Innovive Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Innovive Pharmaceuticals Inc.'s managers have strong backgrounds in cancer, which they are leveraging collectively to seek early-stage drug candidates for speedy development and marketing. The firm looks for high-value compounds that can be differentiated from others already on the market and guided quickly through development. Innovive presently has three potential cancer treatments in its pipeline.
You may also be interested in...
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.